Known targets — ChEMBL curated mechanism
ADRM1PSMA1PSMA2PSMA3PSMA4PSMA5PSMA6PSMA7PSMA8PSMB1PSMB10PSMB11PSMB2PSMB3PSMB4PSMB5PSMB6PSMB7PSMB8PSMB9PSMC1PSMC2PSMC3PSMC4PSMC5PSMC6PSMD1PSMD11PSMD12PSMD13PSMD14PSMD2PSMD3PSMD4PSMD6PSMD7PSMD8SEM1
The experimentally established mechanism targets of Bortezomib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 known ✓ | P28074 | 16/20 | 1.00 |
| ▸ | PSMB8 known ✓ | P28062 | 8/20 | 1.00 |
| ▸ | PSMB9 known ✓ | P28065 | 8/20 | 1.00 |
| ▸ | PSMB6 known ✓ | P28072 | 8/20 | 1.00 |
| ▸ | PSMB10 known ✓ | P40306 | 8/20 | 1.00 |
| ▸ | PSMB11 known ✓ | A5LHX3 | 7/20 | 1.00 |
| ▸ | PSMA7 known ✓ | O14818 | 7/20 | 1.00 |
| ▸ | PSMB1 known ✓ | P20618 | 7/20 | 1.00 |
| ▸ | PSMA1 known ✓ | P25786 | 7/20 | 1.00 |
| ▸ | PSMA2 known ✓ | P25787 | 7/20 | 1.00 |
| ▸ | PSMA3 known ✓ | P25788 | 7/20 | 1.00 |
| ▸ | PSMA4 known ✓ | P25789 | 7/20 | 1.00 |
| ▸ | PSMA5 known ✓ | P28066 | 7/20 | 1.00 |
| ▸ | PSMB4 known ✓ | P28070 | 7/20 | 1.00 |
| ▸ | PSMB3 known ✓ | P49720 | 7/20 | 1.00 |
| ▸ | PSMB2 known ✓ | P49721 | 7/20 | 1.00 |
| ▸ | PSMA6 known ✓ | P60900 | 7/20 | 1.00 |
| ▸ | PSMA8 known ✓ | Q8TAA3 | 7/20 | 1.00 |
| ▸ | PSMB7 known ✓ | Q99436 | 7/20 | 1.00 |
| ▸ | PSMD11 known ✓ | O00231 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bortezomib SCHEMBL8036967 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL29377226 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL466239 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL192129 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL30316729 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8035134 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8049740 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL8099424 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL3676 | 1.00 | PSMB5 (1.00) | PSMB5LONP1PSMB8PSMB9PSMB6 | |
| Bortezomib SCHEMBL17075366 | 0.99 | PSMB5 (0.98) | PSMB5LONP1PSMB8PSMB9PSMB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117820347-A | Method for synthesizing bortezomib by continuous flow | 深圳智微通科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| US-11667654-B2 | Process for the preparation of boronic acid esters | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2023-06-06 | — | — | US | disclosed |
| US-20230023070-A1 | Therapy for the Treatment of Cancer | CELGENE CORPORATION | 2023-01-26 | — | — | US | disclosed |
| US-20210171574-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | MILLENNIUM PHARM INC (US) | 2021-06-10 | — | — | US | disclosed |
| EP-2684167-B1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS INC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200261596-A1 | Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same | PFIZER INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200031850-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BORONIC ACID ESTERS | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2020-01-30 | — | — | US | disclosed |
| EP-3288955-B1 | BORTEZOMIB-BASED DELIVERY SYSTEM | NANOSILICAL DEVICES SRL (IT) | 2019-09-18 | — | — | EP | disclosed |
| US-20190055283-A1 | AZA-PEPTIDE ALDEHYDES AND KETONES | OHIO STATE INNOVATION FOUNDATION | 2019-02-21 | — | — | US | disclosed |
| US-20180208609-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-26 | — | — | US | disclosed |
| US-9051305-B2 | Compositions and methods useful for treating diseases | EUTROPICS PHARMACEUTICALS, INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140221387-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140073580-A1 | COMBINATIONS OF HDAC INHIBITORS AND PROTEASOME INHIBITORS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2014-03-13 | — | — | US | disclosed |
| US-8426355-B2 | Methods of treating muscular wasting diseases using NF-κB activation inhibitors | THERALOGICS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| WO-2012122370-A2 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | EUTROPICS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2011-11-10 | — | — | US | disclosed |
| US-20100226597-A1 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-09-09 | — | — | US | disclosed |
| US-20100226597-A1 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-09-09 | — | — | US | disclosed |
| US-20090131367-A1 | Combinations of HDAC Inhibitors and Proteasome Inhibitors | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2007106884-A2 | METHODS OF TREATING MUSCULAR WASTING DISEASES USING NF-KB ACTIVATION INHIBITORS | THERALOGICS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131367-A1 | Combinations of HDAC Inhibitors and Proteasome Inhibitors | HDAC6, HDAC5, HDAC1 | PSMB5 25/4885PSMB8 39/4885PSMB9 52/4885 |
| US-20110275597-A1 | PHARMACEUTICAL COMPOSITION | BCAT2, TTR, BCAT1 | PSMB5 52/4885PSMB8 1639/4885PSMB9 2145/4885 |
| US-11667654-B2 | Process for the preparation of boronic acid esters | PBRM1, BET1, MALT1 | PSMB5 275/4885PSMB8 1052/4885PSMB9 304/4885 |
| US-20140221387-A1 | COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES | BCL3, MCL1, BCL6 | PSMB5 7/4885PSMB8 49/4885PSMB9 44/4885 |
| US-20100226597-A1 | BORTEZOMIB AND PROCESS FOR PRODUCING SAME | PSMC1, PSMB4, PSMB1 | PSMB5 10/4885PSMB8 11/4885PSMB9 20/4885 |
| US-20230023070-A1 | Therapy for the Treatment of Cancer | HDAC7, HDAC2, HDAC4 | PSMB5 483/4885PSMB8 174/4885PSMB9 225/4885 |
| US-20200261596-A1 | Therapeutic Particles with Peptide Boronic Acid or Boronate Ester Compounds and Methods of Making and Using Same | BCL6, BCL3, BCL9 | PSMB5 1522/4885PSMB8 1324/4885PSMB9 322/4885 |
| US-20200031850-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF BORONIC ACID ESTERS | BET1, PBRM1, BTD | PSMB5 163/4885PSMB8 706/4885PSMB9 220/4885 |
| US-20140073580-A1 | COMBINATIONS OF HDAC INHIBITORS AND PROTEASOME INHIBITORS | HDAC6, HDAC5, HDAC1 | PSMB5 25/4885PSMB8 39/4885PSMB9 52/4885 |
| US-20180208609-A1 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | PSMB5, PSMB11, PSMB3 | PSMB5 1/4885PSMB8 29/4885PSMB9 30/4885 |
| US-20190055283-A1 | AZA-PEPTIDE ALDEHYDES AND KETONES | VIP, DNPEP, PEPD | PSMB5 1154/4885PSMB8 1766/4885PSMB9 1735/4885 |
| US-20210171574-A1 | SYNTHESIS OF BORONIC ESTER AND ACID COMPOUNDS | BTD, BCL6, BRAP | PSMB5 17/4885PSMB8 43/4885PSMB9 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.